Editas Medicine to Participate in Upcoming Investor Conferences.
PorAinvest
miércoles, 27 de agosto de 2025, 1:36 pm ET1 min de lectura
EDIT--
The Wells Fargo Healthcare Conference, scheduled for Wednesday, September 3 in Boston, will feature one-on-one meetings. The Cantor Global Healthcare Conference, taking place on Thursday, September 4 in New York, will feature a fireside chat with a webcast and one-on-one meetings. The Baird Global Healthcare Conference, on Tuesday, September 9 in New York, will include a presentation and one-on-one meetings. Webcasts of Editas Medicine’s presentations will be available on the company's website, with replays available for approximately 30 days following each event.
Editas Medicine is focused on translating the power of CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of transformative in vivo medicines. The company aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine holds exclusive licenses for Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines.
Investors and financial professionals are encouraged to attend these events or access the webcasts for the latest information and updates on Editas Medicine's progress.
References:
[1] https://www.morningstar.com/news/globe-newswire/9518586/editas-medicine-to-participate-in-upcoming-investor-conferences
[2] https://www.globenewswire.com/news-release/2025/08/27/3140088/0/en/Editas-Medicine-to-Participate-in-Upcoming-Investor-Conferences.html
Editas Medicine, a gene editing company, announced management participation in three upcoming investor conferences in September. The events include the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, and Baird Global Healthcare Conference. The presentations will cover the company's pipeline of transformative in vivo medicines for serious diseases. The webcasts and presentations will be available on Editas Medicine's website.
Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, has announced its management's participation in three upcoming investor conferences in September. The events include the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, and Baird Global Healthcare Conference. These conferences will provide investors with an opportunity to learn about the company's pipeline of transformative in vivo medicines for serious diseases.The Wells Fargo Healthcare Conference, scheduled for Wednesday, September 3 in Boston, will feature one-on-one meetings. The Cantor Global Healthcare Conference, taking place on Thursday, September 4 in New York, will feature a fireside chat with a webcast and one-on-one meetings. The Baird Global Healthcare Conference, on Tuesday, September 9 in New York, will include a presentation and one-on-one meetings. Webcasts of Editas Medicine’s presentations will be available on the company's website, with replays available for approximately 30 days following each event.
Editas Medicine is focused on translating the power of CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of transformative in vivo medicines. The company aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine holds exclusive licenses for Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines.
Investors and financial professionals are encouraged to attend these events or access the webcasts for the latest information and updates on Editas Medicine's progress.
References:
[1] https://www.morningstar.com/news/globe-newswire/9518586/editas-medicine-to-participate-in-upcoming-investor-conferences
[2] https://www.globenewswire.com/news-release/2025/08/27/3140088/0/en/Editas-Medicine-to-Participate-in-Upcoming-Investor-Conferences.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios